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Parkinson’s disease, an age-related neurodegenerative disorder, is characterized by the loss 
of dopamine neurons in the substantia nigra, the accumulation of α-synuclein in Lewy bodies 
and neurites, and neuroinflammation. While the exact etiology of sporadic Parkinson’s disease 
remains elusive, a growing body of evidence suggests that misfolded α-synuclein promotes 
inflammation and oxidative stress resulting in neurodegeneration. α-Synuclein has been 
directly linked to microglial activation in vitro and increased numbers of activated microglia 
have been reported in an α-synuclein overexpressing mouse model prior to neuronal loss. 
However, the mechanism by which α-synuclein incites microglial activation has not been fully 
described. Microglial activation is governed in part, by pattern recognition receptors that detect 
foreign material and additionally recognize changes in homeostatic cellular conditions. Upon 
proinflammatory pathway initiation, activated microglia contribute to oxidative stress through 
release of cytokines, nitric oxide, and other reactive oxygen species, which may adversely 
impact adjacent neurons. Here we show that microglia are directly activated by α-synuclein in 
a classical activation pathway that includes alterations in the expression of toll-like receptors. 
These data suggest that α-synuclein can act as a danger-associated molecular pattern.
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and phosphorylation (Conway et al., 1998, 2000, 2001; Hashimoto 
et al., 1999; Kowall et al., 2000; Vila et al., 2000; Perrin et al., 2001; 
Volles et al., 2001; Ding et al., 2002; Shtilerman et al., 2002; Volles 
and Lansbury, 2002; Sharon et al., 2003; Fink, 2006; Tsigelny et al., 
2008b). Multiple lines of evidence suggest that the pathological role of 
α-synuclein is linked to this ability to misfold and self-assemble into 
higher-order structures. In cell culture models, α-synuclein-induced 
cell death has been associated with the formation of oligomeric 
α-synuclein, increased cell membrane conductance, mitochondrial, 
lysosomal and proteasomal dysfunction, and microglial activation 
(Biasini et al., 2004; Zhang et al., 2005; Reynolds et al., 2008; Su et al., 
2008, 2009; Xilouri et al., 2009; Feng et al., 2010). One consequence 
of these synuclein-driven perturbations is an overall increase in oxi-
dative stress which can result from neuronal production of reactive 
oxygen species (ROS), decreased antioxidant responses as well as ROS 
emanating from surrounding activated microglia (Hsu et al., 2000; 
Parihar et al., 2008, 2009). Importantly, studies using α-synuclein 
transgenic models also support that α-synuclein is associated with 
the aforementioned cellular changes, resulting in neuronal dysfunc-
tion and degeneration, microglial activation, and increased oxidative 
stress (Feany and Bender, 2000; He et al., 2001; Dawson et al., 2002; 
Su et al., 2008; Kim et al., 2011).
It is not surprising that Parkinson’s disease patients, most of 
whom have already exhibited a reduction in dopamine content due 
to presynaptic terminal loss, demonstrate an over six-fold increase 
in activated microglia compared to control patients (Ouchi et al., 
2005, 2009; Bartels and Leenders, 2007). While these immune sur-
veillance cells phagocytose cell debris emanating from dying cells 
and dystrophic neurites, the evidence that microglia are activated 
in mouse, rat, and non-human primate models of Parkinson’s 
IntroductIon
Parkinson’s disease is the second most common neurodegenera-
tive disorder, affecting approximately five million people world-
wide. Sporadic as well as familial forms of this disease are typified 
by the loss of substantia nigra pars compacta (SNpc) dopamine 
neurons, dystrophic projections to the striatum, increased oxida-
tion of proteins, lipids and DNA, increased numbers of activated 
microglia, and intracytoplasmic proteinaceous inclusions in the 
surviving SNpc dopamine neurons, called Lewy bodies (Duvoisin, 
1992; Forno, 1996). One major component of Lewy bodies is fibril-
lar α-synuclein, a conformation purported to be toxic to neurons 
(Spillantini et al., 1997; Giasson et al., 1999; Masliah et al., 2000; 
Lee et al., 2001; Song et al., 2004; Periquet et al., 2007; Parihar et al., 
2008; Feng et al., 2010). In addition to its presence in Lewy bodies, 
α-synuclein is further implicated in Parkinson’s disease since point 
mutations and overexpression of the α-synuclein gene, SNCA, are 
associated with familial forms of this disorder (Polymeropoulos 
et al., 1996, 1997; Kruger et al., 1998; Singleton et al., 2003, 2004). 
Moreover, genome-wide association studies (GWAS) have linked 
SNCA polymorphisms with an increased risk for developing spo-
radic Parkinson’s disease (Satake et al., 2009; Simon-Sanchez et al., 
2009; Hamza et al., 2010). While the normal function of α-synuclein 
is not completely understood, genetic and pathological evidence 
suggests that Parkinson’s disease pathogenesis is closely linked with 
a toxic gain-of-function of misfolded α-synuclein.
Whereas native α-synuclein maintains a random coil structure, this 
protein exhibits a propensity to misfold into protofibrils and higher-
order oligomers following changes in pH and ionic strength, increases 
in molecular crowding, and interactions with lipid membranes as well 
as secondary modification such as dopamine adduction, nitrosylation, Frontiers in Neuroscience | Neurodegeneration    June 2011  | Volume 5  |  Article 80  |  2
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UT, USA). All other reagents for cell culture and general use, if not 
indicated, were obtained from Invitrogen (Carlsbad, CA, USA) or 
Sigma-Aldrich (St. Louis, MO, USA).
ExprEssIon, purIfIcatIon, and manIpulatIon of α-synuclEIn
The bacterial expression vector pRK172 containing wild-type human 
α-synuclein cDNA was a kind gift of Dr. Giasson (Giasson et al., 
1999). α-Synuclein was bacterially expressed in Escherichia coli 
BL21 (DE3), purified as previously described, followed by lyophi-
lization and storage at −20°C until use (Maguire-Zeiss et al., 2006). 
The lyophilized protein was resuspended by sonication at 20 Hz 
(2 × 10 s bursts with a 10-s rest between bursts) and diluted to 
1 mg/ml in TEN buffer (10 mM Tris–HCl, pH 7.5, 1 mM EDTA, 
20 mM NaCl) followed by incubation for 5 days at 33–37°C with 
rotation at 1000 rpm (SYNTR, Labnet Orbit M60 shaker; Labnet 
International, Edison, NJ, USA). TEN buffer was incubated in the 
same manner and used as the buffer control for all treatments 
(BufferTR). Endotoxin contamination of the SYNTR and BufferTR was 
evaluated using an E-TOXATE test kit following the manufacturer’s 
instructions (Sigma-Aldrich). The detection limit of the kit was 
0.13 endotoxin units (EU)/ml (10 EU = 1 ng).
charactErIzatIon of α-synuclEIn
Western blot analysis
One microgram of protein was added to denaturing sample 
buffer [62.5 mM Tris, pH 6.8, 10% (v/v) glycerol, 2% (w/v) 
SDS, 5% (v/v) β-mercaptoethanol, and 1% (w/v) bromophenol 
blue], boiled for 90 s, and subjected to polyacrylamide gradient 
(4–20%) gel electrophoresis under denaturing conditions fol-
lowed by transfer to polyvinylidene difluoride (PVDF) mem-
branes (PerkinElmer, Waltham, MA, USA). Membranes were 
blocked in TBST/NFDM [20 mM Tris–HCl pH 7.5, 150 mM 
NaCl, 0.1% (v/v) Tween, 5% (w/v) non-fat dry milk]. Mouse 
anti-α-synuclein primary antibody (1:1000; BD Biosciences, San 
Jose, CA, USA) was used to probe for α-synuclein conformers. 
Immune complexes were visualized on film following incuba-
tion with HRP-conjugated goat anti-mouse secondary antibody 
(1:2000; Chemicon, Temecula, CA, USA) and Super Signal West 
Pico Chemiluminescent Substrate (Thermo Scientific, Waltham, 
MA, USA).
Thioflavin T assay
Forty micromolar Thioflavin T in 10 mM Tris–HCl pH 8.0 (80 μl 
of 50 μM stock) and 12.5 μM SYNTR (20 μl of 62.5 μM stock) or 
20 μl of the appropriate buffer control (BufferTR) were incubated in 
a 96-well black clear bottom plate. Fluorescent measurements were 
obtained using a Fluoromark™ microplate fluorometer (BioRad) 
with an excitation of 450 nm and an emission of 490 nm (Naiki 
et al., 1989; LeVine, 1999). All measurements were performed in 
triplicate in three separate experimental replicates.
Atomic force microscopy
Freshly cleaved muscovite mica was incubated in a mixture of 
1-(3-aminopropyl) silatrane (APS) solution for 30 min to pre-
pare APS-mica. SYNTR or BufferTR was added to the APS-mica 
and allowed to adhere for 2 min, washed with de-ionized water, 
and dried with nitrogen gas (Shlyakhtenko et al., 2000, 2003). 
The mica was attached to a metal disk with double-sided tape for 
  disease prior to frank   neuron death is compelling (Czlonkowska 
et al., 1996; Kohutnicka et al., 1998; Cicchetti et al., 2002; Depino 
et al., 2003; Sugama et al., 2003; Wu et al., 2005; Zhang et al., 2005; 
Cho et al., 2006; Liu, 2006; Qian et al., 2006; Sawada et al., 2006; 
Su et al., 2008, 2009). Also noteworthy are the results from a recent 
GWAS, identifying an association between sporadic Parkinson’s 
disease and a major histocompatibility complex cell surface recep-
tor region on chromosome 6, supporting a role for inflammation 
in the pathogenesis of Parkinson’s disease (Hamza et al., 2010). 
Importantly, α-synuclein leads to increased numbers of activated 
microglia in mouse models of α-synuclein overexpression prior to 
SNpc dopamine neuron death and has a direct effect on microglial 
activation in cell culture experiments (Zhang et al., 2005; Su et al., 
2008, 2009; Theodore et al., 2008; Lee et al., 2010). Although these 
studies demonstrate a direct effect of α-synuclein on microglia, the 
mechanism and type of activation awaits delineation.
Microglia continuously monitor and react to their microenvi-
ronment and activation can be mediated by pattern recognition 
receptors (PRRs) that are specific for pathogen-associated molecu-
lar patterns (PAMPs) such as bacterial- and viral-derived carbohy-
drates, nucleic acids, and lipoproteins (Hu et al., 1996; Muzio et al., 
2000; Lee and Lee, 2002; Block et al., 2007). These receptors are 
localized to microglial membranes and intracellular compartments 
and include families of scavenger receptors and toll-like recep-
tors (TLRs). Once engaged by ligands (e.g., PAMPs), a cascade of 
molecular events ensues which can result in the production and 
release of proinflammatory cytokines (e.g., tumor necrosis factor-α, 
TNF-α and interleukin-1β, IL-1β), nitric oxide, and superoxide: 
a classical activation pathway. Alternatively, microglia can be acti-
vated to produce anti-inflammatory cytokines (e.g., arginase-1 
and transforming growth factor-β) demonstrating the ability of 
these cells to regulate inflammation and allow for repair (Colton 
and Wilcock, 2010). In addition to the typical PAMPs, researchers 
have characterized sterile, non-pathogen related forms of inflam-
mation in which endogenous, disease-related signals, “danger/
damage-associated molecular patterns” (DAMPs), are recognized 
by microglia via PRRs and result in activation (Halle et al., 2008; 
Chen and Nunez, 2010; Duewell et al., 2010; Stewart et al., 2010).
One study suggests that α-synuclein activates microglia through 
a mechanism that involves CD36; however it is likely that other 
PRRs are also required for this activation since microglia derived 
from CD36 knockout mice are still activated following exposure 
to α-synuclein, albeit to a lesser extent (Su et al., 2008, 2009). 
Importantly, the identification of PRRs involved in microglial acti-
vation directed by α-synuclein could provide clinically relevant 
therapeutics. In this study, using a murine microglia cell line (BV-
2) and mouse primary microglia, we determined whether human 
wild-type α-synuclein-mediated microglial activation altered the 
expression of TLRs. Here we report that α-synuclein caused direct 
microglial activation with classical cytokine upregulation, increased 
expression of antioxidant response enzymes and demonstrate for 
the first time changes in TLR gene expression.
matErIals and mEthods
chEmIcals and rEagEnts
Dulbecco’s modified Eagle medium (DMEM) and minimum essen-
tial medium (MEM) were obtained from Cellgro (St. Louis, MO, 
USA). Fetal bovine serum was purchased from Hyclone (Logan, www.frontiersin.org  June 2011  | Volume 5  |  Article 80  |  3
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qRT-PCR
RNA was reverse transcribed in a 20 μl reaction using a High-Capacity 
cDNA Archive Kit (Applied Biosystems, Carlsbad, CA, USA). The 
quality of cDNA was verified following RT-PCR for β-actin expres-
sion. cDNA samples (10 μl) were then added to 90 μl of TaqMan® 
Universal PCR master mix and loaded onto TaqMan® low density 
arrays (TLDA) preloaded with probes and primers for various targets 
and one endogenous control (see figure legends and Tables 1 and 2). 
Additional gene targets were assayed in a 96-well plate format, where 
2.5 μl of cDNA from each sample was added to 17.5 μl of master 
mix containing the appropriate primer/probe pairs and TaqMan® 
Universal PCR master mix. All real-time PCR were run using the ABI 
Prism 7900HT Sequence Detection System (Applied Biosystems). The 
results were analyzed using the relative quantification ∆∆Ct method, 
normalizing samples to endogenous controls, either 18S rRNA 
(TLDA) or GAPDH (individual targets) followed by normalization to 
the appropriate BufferTR treated controls. All measurements were per-
formed in triplicate in three separate biological replicates. (Primers/
Probes used: TNF-α Mm00443258_m1, IL-1β Mm0434228_m1, 
NfkB1 Mm0047361_m1, Aif1 Mm00479862_g1, TLR1 Mm0120884_
m1, TLR2 Mm00442346_m1, TLR3 Mm00446577_g1, TLR4 
Mm00445273_m1, TLR6 Mm01208943_s1, TLR7 Mm00446590_m1, 
TLR9 Mm00446193, Myd88 Mm01351743, Scarb1 Mm00450234_
m1, Hmox1 Mm00516004_m1, Prdx1 Mm01621996_s1, 18S rRNA 
Hs99999901_s1, and GAPDH 4352339E.) Statistical analysis was per-
formed by Student’s t-test on ∆Ct values and the significance level was 
set at P < 0.05. Gene expression changes are graphically represented 
as fold change (2−∆∆Ct).
Western blot analysis
BV-2 cells were treated as described above. Following treatment, 
cells were washed with ice-cold PBS and lysed on ice in modified 
RIPA buffer (50 mM Tris–HCl pH 7.4, 1% (v/v) NP-40, 0.25% (w/v) 
sodium deoxycholate, 150 mM NaCl) supplemented with Protease 
Inhibitor Cocktail (for mammalian cells; Sigma-Aldrich). Cell lysates 
were subjected to gentle rotation for 20 min at 4°C then sonicated at 
18 Hz (3 × 10 s bursts with 30 s rest between bursts). Lysates were 
cleared by centrifugation at 17,000 rpm for 10 min at 4°C. Cleared 
lysates (25 μg) were treated as described in above and subjected 
to denaturing polyacrylamide gel electrophoresis (10%) followed 
by transfer to PVDF membranes (PerkinElmer). Membranes were 
blocked in TBST/NFDM [20 mM Tris–HCl pH 7.5, 150 mM NaCl, 
0.1% (v/v) Tween, 5% (w/v) non-fat dry milk] followed by incuba-
tion with mouse anti-heme oxygenase-1 primary antibody (HO-1; 
1:1000; Abcam, Cambridge, MA, USA). Immune complexes were 
visualized on film following incubation with HRP-conjugated goat 
anti-mouse secondary antibody (1:2000; Chemicon) and Super 
Signal West Pico Chemiluminescent Substrate. Membranes were 
reprobed with α-tubulin (1:1000; Abcam), which served as the 
loading control. Densitometric analysis of digitized images was 
completed using the EC3 Imaging System (UVP, Upland, CA, USA).
statIstIcal analysIs
All statistical analyses were carried out using Graphpad Prism 5 
(Graphpad Software Inc., La Jolla, CA, USA). An ANOVA was per-
formed followed by Bonferroni’s post hoc test or Student’s t-test 
where appropriate. All data are reported as mean ± SD. P-values 
≤0.05 were considered significant.
imaging. Images were acquired in tapping mode, using silicon tap-
ping mode probes and a Multimode SPM Nanoscope IIIa system 
(Veeco/Digital Instruments, Santa Barbara, CA, USA). Nominal 
spring constants of 60 N/m and a resonant frequency of 245 Hz 
were used.
cEll culturE
BV-2 microglia treatment
BV-2 murine microglial cells (BV-2 cells) were plated at a density 
of 5 × 105 cells per well (6-well plates) in 2 ml of DMEM sup-
plemented with 5% fetal bovine serum and allowed to adhere for 
24 h (Blasi et al., 1990; Horvath et al., 2008; Henn et al., 2009). One 
hour prior to treatment, serum-containing media was replaced 
with serum-free DMEM. Cells were subsequently treated with 
50 nM SYNTR or BufferTR in DMEM for various time points as 
indicated in the figure legends. Following treatment, media were 
collected, centrifuged at 1000 rpm for 2 min and stored at −20°C 
until assayed. All treatments were preformed in triplicate in three 
separate biological replicates.
TNF-α secretion
Tumor necrosis factor-α levels in the media of treated microglia 
were measured by an enzyme-linked immunosorbent assay (ELISA) 
according to the manufacturer’s instructions (R&D Systems, 
Minneapolis, MN, USA). All measurements were performed in 
triplicate in three separate biological replicates.
Nitric oxide release
Nitric oxide (NO) release into the media of treated microglia was 
determined by measuring the stable NO metabolite, nitrite, using 
a Greiss reagent assay kit according to the manufacturer’s instruc-
tions (Invitrogen). All measurements were performed in triplicate 
in three separate biological replicates.
Preparation and treatment of primary microglia
Primary microglia cultures were prepared from P1 to P3 C57Bl/6 
mouse cortices as previously described (Su et al., 2008) except 
that microglia were isolated from mixed glial cultures (∼DIV 
14) by shaking at 125 rpm for 5 h at 37°C on a rotary shaker 
and collecting the microglia-enriched medium. Microglia were 
plated at a density of 5 × 105 cells per well (6-well plates) in 2 ml 
of MEM supplemented with 0.01% pyruvate, 0.6% glucose, and 
5% fetal bovine serum (microglia growth media) and allowed 
to adhere for 24 h. Cells were subsequently treated with 50 nM 
SYNTR or BufferTR in microglia growth media for 24 h. All treat-
ments were preformed in triplicate in two separate biological 
replicates. Animals were maintained and treated in accordance 
with the regulatory standards of the Animal Welfare Act and 
approved for use by the Georgetown University Animal Care 
and Use Committee.
RNA extraction
Following treatment, RNA was harvested from cultured cells using 
an RNeasy mini kit and on-column DNase I digestion according 
to the manufacturer’s instructions (Qiagen, Valencia, CA, USA). 
RNA purity was assessed using an Agilent 2100 bioanalyzer (Santa 
Clara, CA, USA) and concentration measured using a NanoDrop 
1000 spectrophotometer (Thermo Scientific).Frontiers in Neuroscience | Neurodegeneration    June 2011  | Volume 5  |  Article 80  |  4
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syntr InducEs classIcal mIcroglIal actIvatIon
To determine whether SYNTR directly activates microglia through 
the classical activation pathway we treated a microglia cell line, BV-2 
cells, with SYNTR and assayed for markers of inflammation. When 
classically activated, microglia adapt morphological changes and 
secrete proinflammatory mediators such as NO, TNF-α, and IL-1β 
(Banati et al., 1993; Combs et al., 2001; Lee and Lee, 2002; Kim 
and Joh, 2006; Colton and Wilcock, 2010). Previous studies have 
demonstrated that the secretion of proinflammatory mediators 
from activated microglia is a time-dependent process; therefore, 
we examined the temporal response of BV-2 cells to SYNTR treat-
ment (Lee and Lee, 2002; Zhang et al., 2005; Su et al., 2008, 2009). 
Microglia were treated with SYNTR (50 nM) or BufferTR for 2–36 h 
and the amount of nitrite, a stable NO metabolite, was quantified 
in the conditioned media (Figure 2; a dose response curve was used 
to identify this concentration of SYNTR; data not shown). NO secre-
tion was first detected 6 h post-SYNTR treatment with maximum 
production observed at 24 h (P ≤ 0.05). We therefore chose 24 h 
post-treatment for all subsequent analyses. To further characterize 
BV-2 activation in response to α-synuclein, we examined release of 
the prototypical proinflammatory mediator TNF-α. Twenty-four 
hours after SYNTR treatment there was a significant increase in 
TNF-α released into the BV-2 cell conditioned media compared to 
media from BufferTR treated cells (Figure 3A; P ≤ 0.05). Although 
the release of TNF-α protein was increased in SYNTR-treated BV-2 
cells there was not a significant increase in the gene expression for 
this target (Table 1). However, using qRT-PCR we determined that 
the gene expression level of a second prototypical proinflammatory 
molecule, IL-1β, was significantly upregulated compared to con-
trol conditions following SYNTR treatment (Figure 3B; P ≤ 0.05). 
Taken together, these data establish that α-synuclein stimulates 
the production and release of classical proinflammatory molecules 
from BV-2 cells.
syntr uprEgulatEs antIoxIdant EnzymEs
One consequence of NO and proinflammatory molecule production 
in glia is an overall increase in oxidative stress. Microglia are capa-
ble of responding to oxidative stress by increasing the expression of 
  antioxidant response genes that are regulated by the transcription 
factor Nrf-2 [Nuclear factor (erythroid-derived 2)-like 2; Chowdhury 
et al., 2009; Bast et al., 2010]. The upregulation of these phase II detoxi-
fication enzymes provides cellular protection from oxidative stress. 
Therefore, we investigated whether two Nrf-2 regulated enzymes, 
peroxiredoxin-1 (PRDX-1), and heme oxygenase-1 (HO-1), both 
previously associated with activated microglia, were altered following 
SYNTR or BufferTR treatment (Kitamura et al., 1998a,b; Tanaka et al., 
2006; Bast et al., 2010). cDNA was prepared from SYNTR and BufferTR 
treated BV-2 cells and qRT-PCR performed to interrogate PRDX1 and 
HMOX1 expression levels. As predicted, the expression levels of both 
antioxidant response genes were significantly upregulated in SYNTR-
treated BV-2 cells compared with BufferTR treated cells (Figures 4A,B; 
P ≤ 0.05). To validate the gene expression findings, HO-1 protein levels 
were analyzed in lysates from SYNTR-treated BV-2 cells by Western blot 
analysis. SYNTR treatment of these cells caused a significant upregula-
tion of HO-1 protein, confirming the qRT-PCR results (Figures 4C,D; 
P ≤ 0.05). These data demonstrate a robust BV-2 cell derived antioxi-
dant response following treatment with SYNTR.
rEsults
charactErIzatIon of manIpulatEd α-synuclEIn
The mechanism by which α-synuclein activates microglia 
is unknown, but purported to be involved in Parkinson’s 
disease pathogenesis (Zhang et al., 2005; Thomas et al., 
2007; Su et al., 2008, 2009). In order to investigate the 
response of microglia to α-synuclein, we prepared recombi-
nant human wild-type α-synuclein which was subsequently 
incubated for 5 days at 33–37°C (T) with mechanical rota-
tion at 1000 rpm (R). The resultant α-synuclein, SYNTR, was 
tested for endotoxin contamination, which was found to be 
below the detectable limit of the assay (<0.013 ng/ml; data 
not shown). First, to determine whether our preparation 
included SDS-stable oligomers, SYNTR was subjected to poly-
acrylamide gel electrophoresis under denaturing conditions, 
followed by Western blot analysis. As shown in Figure 1A, 
SYNTR contains monomeric as well as SDS-stable oligomers 
of α-synuclein (arrows). We next determined whether our 
preparation contained amyloid fibrils by measuring the exci-
tation/emission spectra following incubation with Thioflavin 
T. We show in Figure 1B enhanced Thioflavin T fluorescence 
following incubation with SYNTR, suggesting the presence of 
amyloid fibrils (P ≤ 0.05; Figure 1B). Lastly, we characterized 
SYNTR under non-denaturing conditions using atomic force 
microscopy (AFM) to visualize the height and distribution 
of α-synuclein conformers (Figures 1C,D). The largest pro-
portion of SYNTR had a height of <5 nm, likely represent-
ing monomeric α-synuclein, but amorphous aggregates of 
>10 nm were also present. Together, these data establish that 
SYNTR contains monomers, SDS-stable oligomers, amorphous 
aggregates and amyloid structures.
Table 1 | Gene expression changes following SYNTR treatment of BV-2 
microglia1.
Gene  Expression  Fold difference3  P-value 
  following SYNTR  (compared 
 treatment2  to buffer)
TLR1  NSD –  0.07
TLR2  Upregulated 3  0.03
TLR3  Upregulated 3  0.04
TLR4  NSD –  0.43
TLR6  NSD –  0.48
TLR7  Downregulated 1  0.04
TLR9  NSD –  0.30
MYD88  NSD –  0.85
AIF1 (IBA-1)  NSD –  0.25
SCARB  NSD –  0.46 
(CD36)
TNFα NSD  –  0.06
NFκB NSD  –  0.07
1BV-2 microglia were treated with 50 nM SYNTR or BufferTR for 24 h.
2NSD indicates no significant difference in gene expression compared to buffer 
treated cells.
3Fold difference = 2−∆∆Ct.www.frontiersin.org  June 2011  | Volume 5  |  Article 80  |  5
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syntr-dIrEctEd mIcroglIal actIvatIon altErs tlr gEnE 
ExprEssIon
Thus far we have established that SYNTR directly activates BV-2 
cells inciting the expression and release of proinflammatory mol-
ecules and the upregulation of antioxidant response enzymes. Since 
FiGuRE 1 | Manipulation of α-synuclein results in the formation of 
aggregates. (A) α-Synuclein prepared in TEN buffer or TEN buffer alone was 
incubated at 33–37°C with mechanical rotation (1000 rpm) for 5 days (SYNTR; 
BufferTR). SYNTR was then subjected to anti-synuclein Western blot analysis 
following separation on a 4–20% Tris–glycine polyacrylamide gel under 
denaturing conditions. Arrows indicate SDS-stable α-synuclein aggregates. 
(B) Thioflavin T fluorescence measurements were obtained using an excitation 
wavelength of 450 nm and an emission wavelength of 490 nm. SYNTR contains 
amyloid fibrils (*P < 0.05; each data point represents mean ± SD, n = 3). (C) 
SYNTR and BufferTR were subjected to AFM. This analysis demonstrated the 
formation of α-synuclein aggregates in the SYNTR samples. AFM height images 
of SYNTR and similarly manipulated buffer are shown with the height of 
aggregates displayed along the z-axis. Height images shown at 
2 μm × 2 μm × 2 μm. (D) AFM height measurements of SYNTR. The largest 
proportion of SYNTR had a height of <5 nm, likely representing monomeric 
α-synuclein, but aggregates of >10 nm were also present.
FiGuRE 2 | SYNTR treatment stimulates nitric oxide (NO) release from 
microglia. BV-2 cells were treated with 50 nM of SYNTR or BufferTR for 2–36 h. 
Following treatment, a Greiss reagent assay was performed on the 
conditioned media to determine NO release and subsequent nitrite 
production. NO release was significantly higher in cells treated with SYNTR 
than buffer control beginning at 6 h of treatment (*P < 0.05, n = 3). NO release 
reached a maximum by 24 h of treatment. Nitrite concentrations are 
represented as mean ± SD; ND indicates none detected.
Table 2 | Gene expression changes following SYNTR treatment of 
Primary microglia1.
Gene  Expression  Fold difference3  P-value 
  following SYNTR  (compared 
 treatment2  to buffer)
TLR1  Upregulated 9  0.002
TLR2  Upregulated 7  0.002
TLR3  Upregulated 4  <0.001
TLR4  Downregulated 1.7  0.049
TLR6  NSD –  0.072
TLR7  Upregulated 1.4  0.014
TLR9  NSD –  0.264
MYD88  Upregulated 3  0.011
AIF1 (IBA-1)  Upregulated 5  0.002
SCARB  Downregulated 1.5  0.028 
(CD36)
TNFα  Upregulated 16  0.001
IL1β  Upregulated 240  <0.001
NFκB  Upregulated 3  0.002
1Primary microglia were treated with 50 nM SYNTR or BufferTR for 24 h.
2NSD indicates no significant difference in gene expression compared to buffer 
treated cells.
3Fold difference = 2−∆∆Ct.Frontiers in Neuroscience | Neurodegeneration    June 2011  | Volume 5  |  Article 80  |  6
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dIscussIon
The novel finding of this paper is that α-synuclein activates BV-2 
and primary microglia through a classical pathway that includes 
the upregulation of TLR expression. We also show that α-synuclein 
mediates a robust increase in the expression of antioxidant response 
genes. Together these results support a role for α-synuclein as a 
DAMP capable of activating microglial PRRs and inciting oxida-
tive stress.
Specifically, we demonstrate that BV-2 cells exposed to SYNTR 
show increased release of TNF-α protein and NO as well as increased 
IL1β gene expression, all indicative of a classical   activation path-
way (Colton, 2009). Importantly, SYNTR also increases prototypical 
proinflammatory molecule gene expression in primary microglia 
(TNFα, IL1β). The upregulation and release of proinflammatory 
molecules following treatment of microglia with wild-type, mutant, 
or aggregated α-synuclein has been previously shown, but the acti-
vation mechanism is poorly understood (Zhang et al., 2005; Su 
et al., 2008, 2009). One study demonstrated that primary micro-
glia derived from CD36 knockout mice had a reduced response to 
exogenous α-synuclein treatment, suggesting a function for this 
scavenger receptor in activation (Su et al., 2008). Here we con-
firm previous findings regarding α-synuclein’s ability to stimulate 
microglia through a classical pathway and extend our understand-
ing of this activation by demonstrating a role for the TLR family 
of PRRs.
Pattern recognition receptors are associated both with mem-
branes on the cell surface and organelles within microglia, and 
respond to specific ligands by altering downstream molecular path-
ways leading to altered transcription of NFκB-, C-Jun-, IRF7-, and 
CREB-regulated genes (Ajmone-Cat et al., 2003; Ousman et al., 
2005; Waetzig et al., 2005; Colton, 2009). The pattern of transcrip-
tional activation represents a specific microglial activation state 
classified as classical activation, alternative activation and acquired 
deactivation (Colton, 2009). Our data suggest that SYNTR induces 
a classical activation pathway since the prototypical proinflam-
matory molecules, NO, TNF-α, and IL-1β, are increased. It is rel-
evant that these proinflammatory molecules are also elevated in 
Parkinson’s disease patients (Blum-Degen et al., 1995; Knott et al., 
2000; Nagatsu et al., 2000). Additionally, we demonstrate a robust 
increase in HO-1 following treatment of BV-2 cells with SYNTR. 
HO-1 is a member of the inducible phase II detoxification enzyme 
family of genes with transcription regulated by the antioxidant 
response element binding protein Nrf-2 (Moi et al., 1994; Alam 
et al., 1999; Kensler et al., 2007; Paine et al., 2010). Under cellular 
stress, HO-1 helps to maintain antioxidant/oxidant homeostasis 
by degrading free heme into carbon monoxide, biliverdin, and free 
iron (Paine et al., 2010). In Parkinson’s disease patients there is an 
increase in HO-1 in substantia nigra dopamine neurons and in 
Lewy bodies (Castellani et al., 1996; Schipper et al., 1998; Schipper, 
2004). In our reduced system we are examining the direct role of 
SYNTR on BV-2 cells and find that increased oxidative stress aug-
ments HO-1 expression.
Most notably, we have shown for the first time that SYNTR-
mediated microglial activation modulates TLR expression. We 
demonstrate that these changes in TLR expression occur in both 
the BV-2 cell line and primary microglia derived from mouse 
cortices. It is interesting that the primary microglia have a more 
microglial activation is in part mediated through the engagement 
of DAMPs we asked whether the expression of classic PRRs was 
altered following exposure to SYNTR. BV-2 cells were treated with 
BufferTR or SYNTR, 24 h later RNA was prepared and gene expression 
levels for PRRs, co-receptors, and proinflammatory molecules were 
quantified (Table 1). Here, we show for the first time, a significant 
upregulation of TLR2 and TLR3 expression with a concomitant 
downregulation of TLR7 expression following SYNTR treatment 
of BV-2 cells (Table 1). The other targets were not significantly 
changed. Next we asked whether primary microglia derived from 
mouse cortices demonstrate similar SYNTR-mediated changes in 
gene expression. Similar to BV-2 cells, primary microglia dem-
onstrate a significant upregulation of TLR2 and TLR3 expression 
following SYNTR treatment (Table 2). In addition, the expression of 
TLR1, TLR7, MYD88, IBA-1, NFκB, TNFα, and IL1β were all sig-
nificantly increased while the expression of other gene targets were 
either unchanged or decreased (TLR4, TLR6, TLR9, CD36). These 
data support and extend previous observations that α-synuclein 
directly activates primary microglia through a classical activation 
pathway which we now show includes a role for TLRs.
FiGuRE 3 | SYNTR treatment increases the expression and release of 
proinflammatory molecules. (A) BV-2 cells were treated with 50 nM of 
SYNTR or BufferTR for 24 h. Following treatment, the conditioned media were 
evaluated for TNF-α protein secretion using an ELISA. Cells treated with SYNTR 
released significantly more TNF-α than BufferTR treated microglia (ND indicates 
none detected; *P < 0.05, n = 3). (B) Quantitative RT-PCR for IL1β was 
performed on cDNA from SYNTR and buffer treated cells. Microglia treated 
with SYNTR had significantly higher expression of IL1β than buffer treated cells 
(*P < 0.05; n = 3). Expression values were normalized to 18S rRNA as an 
internal control. Statistics were performed on ∆Ct values.www.frontiersin.org  June 2011  | Volume 5  |  Article 80  |  7
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to be   determined. However, another pathogenic protein, fibril-
lar β-amyloid, acts as a DAMP activating microglia via TLR2, 
TLR4, and TLR6 as well as the scavenger receptors, CD14 and 
CD36 supporting the dual role of TLRs as mediators of glial acti-
vation by both exogenous and endogenous ligands (El Khoury 
et al., 2003; Jana et al., 2008; Jin et al., 2008; Reed-Geaghan et al., 
2009; Stewart et al., 2010). In this study we demonstrate a direct 
activation of microglia by α-synuclein and we hypothesize that 
α-synuclein also acts as a TLR ligand. First, due to its hydrophobic 
nature, α-synuclein may bind directly to TLRs since molecules 
with high hydrophobicity have been shown to contribute to 
proinflammatory events through interaction with TLRs (Seong 
and Matzinger, 2004). Second, Lee et al. (2008) have shown that 
fibrillar α-synuclein, once internalized, is trafficked along the 
endosomal pathway before it is eventually degraded in the lyso-
some. Therefore, it is conceivable that α-synuclein is available to 
robust response to SYNTR with greater-fold increases in TLR and 
proinflammatory gene expression than BV-2 cells. TLR1 and TLR2 
belong to a subfamily of TLRs that can bind to and be activated 
by hydrophobic ligands. These TLRs are found on the surface 
of microglia where they can heterodimerize with each other or 
with other PRRs to facilitate downstream signaling events (Jin 
and Lee, 2008; O’Neill et al., 2009). TLR1 and TLR2 are associ-
ated with a wide range of fungal, microbial, and endogenous 
ligands including other misfolded proteins (El Khoury et al., 
2003; Jana et al., 2008; Jin et al., 2008; Reed-Geaghan et al., 2009; 
Stewart et al., 2010). In contrast, TLR3 and TLR7 belong to a 
single-domain family of TLRs, are localized to endosomes and 
are associated with the recognition of nucleic acids (O’Neill et al., 
2009). Both are potent anti-viral TLRs responding to dsRNA and 
subsequently activating innate immune responses. The exact role 
of TLRs in α-synuclein-mediated microglial activation remains 
FiGuRE 4 | SYNTR treatment increases the expression of antioxidant 
response genes. (A) Quantitative RT-PCR for (A) peroxiredoxin-1 (PRDX1) and 
(B) heme oxygenase-1 (HMOX1) was performed on cDNA from BufferTR- or 
SYNTR-treated BV-2 cells. Cells treated with SYNTR (50 nM) had a significantly 
higher expression of PRDX1 and HMOX1 compared to buffer treated cells 
(BufferTR; *P < 0.05). Expression values were normalized to GAPDH as an 
internal control. Statistics were performed on ∆Ct values. (C) Representative 
HO-1 Western blot analysis of BV-2 cell lysates following treatment. BV-2 cells 
were treated with 50 nM SYNTR or BufferTR for 24 h. Protein lysates were 
prepared and subjected to 10% SDS-polyacrylamide gel electrophoresis and 
immunoblotted for HO-1. Blots were reprobed for α-tubulin as a loading control. 
(D) Immunocomplexes were quantified by densitometric analysis and 
normalized to the loading control. BV-2 cells treated with SYNTR had significantly 
higher levels of HO-1 protein than buffer treated cells (BufferTR; *P < 0.05; n = 3).Frontiers in Neuroscience | Neurodegeneration    June 2011  | Volume 5  |  Article 80  |  8
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